NEW YORK, NY / ACCESSWIRE / July 7, 2017 / U.S. markets continued to be dragged down by a selloff in technology stocks. The Dow Jones Industrial Average declined 0.74 percent to close at 21,320.04, while the S&P 500 Index fell 0.94 percent to close at 2,409.75. The tech-heavy Nasdaq Composite Index dropped 1.00 percent to close at 6,089.46.

"The rotation out of tech is dominating stocks and is the overarching theme in the market," said Mike Antonelli, equity sales trader at Robert W. Baird & Co. "People should not mistake rotation for volatility, and I am not terribly freaked out as investors are not selling everything equally."

"Technology has four times greater impact on the averages than oil because of technology's massive percentage of the capitalization of the S&P," said Kent Engelke, chief economic strategist at Capitol Securities Management Inc. "The amount of monies required to keep the megasized technology growth issues at current levels is gargantuan."

RDI Initiates Coverage on:

BioCryst Pharmaceuticals Inc.
https://ub.rdinvesting.com/news/?ticker=BCRX

Exact Sciences Corporation
https://ub.rdinvesting.com/news/?ticker=EXAS

BioCryst Pharmaceuticals Inc.'s stock moved 3.24% lower Thursday, to close the day at $5.67. The stock recorded a trading volume of 543,351 shares, which was below its three months average volume of 1,721,950 shares. In the last year BioCryst Pharmaceuticals Inc.'s shares have traded in a range of 2.82 - 9.25. The share price has gained 101.06% from its 52 week low. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $5.65 is below its 200-day moving average of $6.50. Shares of BioCryst Pharmaceuticals have fallen approximately 10.43 percent year-to-date.

Access RDI's BioCryst Pharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=BCRX

On Thursday, shares in Exact Sciences Corporation recorded a trading volume of 1,516,012 shares, which was below the three months average volume of 3,401,490 shares. The stock ended the day 0.14% lower at 36.02. The share price has gained 213.76% from its 52 week low with a 52 week trading range of 11.48 - 38.92.The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $33.86 is greater than its 200-day moving average of $24.14. Shares of Exact Sciences have gained approximately 169.61 percent year-to-date.

Access RDI's Exact Sciences Research Report at:
https://ub.rdinvesting.com/news/?ticker=EXAS

Our Actionable Research on BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) and Exact Sciences Corporation (NASDAQ: EXAS) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com